Your session is about to expire
← Back to Search
Anti-helminthic
Niclosamide for Coronavirus (RESERVOIR Trial)
Phase 2
Waitlist Available
Research Sponsored by Entero Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 43
Summary
This trial is testing a treatment for adults who have COVID-19 and also suffer from gastrointestinal infections. The goal is to see if this treatment can help improve their condition.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 to day 43
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 43
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Fecal RNA Virus Clearance
SAEs
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Alkaline Phosphatase, AST, ALT, and LDH)
+8 moreSecondary study objectives
Clinical Severity Score
Time to Resolution of Diarrhea
Side effects data
From 2021 Phase 2 trial • 73 Patients • NCT0439935621%
Nausea
9%
Skin rash
6%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control Group
Niclosamide- Experimental Group
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NiclosamideExperimental Treatment1 Intervention
Niclosamide tablets 400 mg 3 times daily for 14 days
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo tablets 3 times daily for 14 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niclosamide
2017
Completed Phase 3
~2280
Find a Location
Who is running the clinical trial?
Entero TherapeuticsLead Sponsor
9 Previous Clinical Trials
244 Total Patients Enrolled
First Wave Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
108 Total Patients Enrolled
AzurRx BioPharma, Inc.Lead Sponsor
2 Previous Clinical Trials
68 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger